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Early detection, clinical management and disease recurrence monitoring are critical areas in cancer treatment in which specific
biomarker panels are likely to be very important in each of these key areas. We have previously demonstrated that levels of
alpha-2-heremans-schmid-glycoprotein (AHSG), complement component C3 (C3), clusterin (CLI), haptoglobin (HP) and serum
amyloid A (SAA) are significantly altered in serum from patients with squamous cell carcinoma of the lung. Here, we report
the abundance levels for these proteins in serum samples from patients with advanced breast cancer, colorectal cancer (CRC)
and lung cancer compared to healthy controls (age and gender matched) using commercially available enzyme-linked
immunosorbent assay kits. Logistic regression (LR) models were fitted to the resulting data, and the classification ability of
the proteins was evaluated using receiver-operating characteristic curve and leave-one-out cross-validation (LOOCV). The most
accurate individual candidate biomarkers were C3 for breast cancer [area under the curve (AUC) 5 0.89, LOOCV 5 73%], CLI
for CRC (AUC 5 0.98, LOOCV 5 90%), HP for small cell lung carcinoma (AUC 5 0.97, LOOCV 5 88%), C3 for lung
adenocarcinoma (AUC 5 0.94, LOOCV 5 89%) and HP for squamous cell carcinoma of the lung (AUC 5 0.94, LOOCV 5 87%).
The best dual combination of biomarkers using LR analysis were found to be AHSG 1 C3 (AUC 5 0.91, LOOCV 5 83%) for
breast cancer, CLI 1 HP (AUC 5 0.98, LOOCV 5 92%) for CRC, C3 1 SAA (AUC 5 0.97, LOOCV 5 91%) for small cell lung
carcinoma and HP 1 SAA for both adenocarcinoma (AUC 5 0.98, LOOCV 5 96%) and squamous cell carcinoma of the lung
(AUC 5 0.98, LOOCV 5 84%). The high AUC values reported here indicated that these candidate biomarkers
have the potential to discriminate accurately between control and cancer groups both individually and in combination with
other proteins.
Despite the recent good news that cancer incidence and
death rates for men and women continue to decline in devel-
oped countries, cancer is projected to become the leading
cause of death worldwide this year.1 For women, breast can-
cer is the most common, with lung cancer second and colo-
rectal cancer (CRC) third.2 For men, prostate cancer is the
most prevalent form of cancer, followed by lung cancer and
then CRC.3
The number of candidate biomarkers, which can be used
for diagnosis, early detection or treatment monitoring, con-
tinues to grow rapidly; however, few of these reach the clinic
mainly because of low levels of sensitivity and specificity.4
Despite advances in new technologies, detection and routine
measurement of low abundant tumor-specific proteins
remain a significant challenge. The detection limits of mod-
ern mass spectrometers and conventional immunoassays are
now, however approaching the relevant levels in biofluids
such as serum, although it is likely that some early stage dis-
ease-specific biomarkers may still lie beyond current limits.5
Coupled with the added difficulties of high-abundance resi-
dent proteins such as albumin masking the low abundant tu-
mor-specific biomarkers and the fact that some biomarkers
are rapidly degraded, and identification of low level proteins
remains difficult.6 Much of the focus on sample preparation
for biomarker discovery experiments has focused on the
removal of highly abundant proteins such as albumin and
haptoglobin, a strategy that results in relative enrichment of
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medium to low abundant potential biomarkers. Within the
high abundant protein group reside the acute-phase proteins
(APPs). APPs generally have a nonspecific rapid response to
such processes as inflammation/infections, tissue damage,
surgery, myocardial infarction or the presence of tumors. The
relationship between the APPs and cancer has been well
documented in the literature with numerous investigations
reporting on altered levels of various APPs with different
types of cancers and evidence that many APPs are actually
produced directly by tumor tissue.7,8
It has been suggested that APPs were not likely to be specific
for any type of cancer and would be expected to be elevated in
all malignancies and in inflammatory diseases. In addition,
high-abundance proteins such as the APPs were thought
unlikely to be tumor-derived and thus to represent cancer epi-
phenomena rather than direct tumor-derived proteins. Recent
progress in proteomics studies, however, which profiled the se-
rum proteins of patients with cancer and those of normal indi-
viduals, indicated that the altered expression of APPs was dif-
ferent for distinct types, subtypes, and even stages of cancer.9,10
It is likely that panels of biomarkers in the future will be com-
prised of biomarkers that reflect tumor-specific proteins to-
gether with proteins from the tumor microenvironment.
Our study focused on the measurement of five highly
abundant serum proteins from the APP class, which we have
previously found to be altered in serum from patients with
squamous cell carcinoma of the lung,11 in advanced breast,
CRC and lung cancer serum. Specifically, the levels of alpha-
2-heremans-schmid-glycoprotein (AHSG), complement com-
ponent C3 (C3), clusterin (CLI), haptoglobin (HP) and serum
amyloid A (SAA) were measured.
Material and Methods
Patients and sample collection
Samples were collected through a collaborative project involv-
ing participating sites (St Vincent’s University Hospital, Dub-
lin 4, Ireland and St. James’s Hospital, Dublin 8, Ireland),
coordinated through ICORG (the All Ireland Co-operative
Oncology Research Group, www.icorg.ie). The samples were
collected according to standard phlebotomy procedures from
consented patients. Ethical consent was granted from each of
the respective Hospital Ethics Committees. A total of 10 ml
of blood was collected into additive free (serum) blood tubes
and was allowed to clot for 30 min to 1 hr at room tempera-
ture. The serum was denuded by pipette from the clot and
poured into a clean tube. The tubes were centrifuged at 400g
for 30 min at 4C. Serum was aliquoted in the cryovial tubes,
labeled and stored at 80C until time of analysis. The time
from sample procurement to storage at 80C was less than
3 hr. Each serum sample underwent not more than three
freeze/thaw cycles prior to analysis.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA)-based analysis
was carried out using raw unfractionated serum samples.
Each sample was analyzed in triplicate using the following
commercially available kits, for the measurement of serum
haptoglobin (AssayPro), CLI (BioVendor R&D), complement
C3 (AssayPro), SAA (Invitrogen) and alpha HS glycoprotein
(AssayPro) kits were used. The ELISA assays were performed
according to each manufacturer’s protocol and guidelines.
The haptoglobin and complement C3 assays use a quantita-
tive and competitive enzyme immunoassay technique that
takes 2–3 hr to perform. The assays for alpha HS glycopro-
tein, CLI and SAA use a quantitative sandwich enzyme im-
munoassay technique that takes 3–4 hr to perform. The opti-
cal density (OD) was measured using a microplate reader
(Bio-Tek), and the concentration of each protein in the se-
rum samples was determined by comparing the OD of the
samples against the respective standard curve.
Statistical analysis
Box-and-whisker plots were generated through Microsoft
Excel using the values from the ELISA data. The plots display
a statistical summary including the median, quartiles and
range. Student t-test was used to identify statistically signifi-
cant changes in abundance levels for specific proteins
between patient with cancer and control serum samples. Re-
ceiver-operating characteristic (ROC) curve analysis was per-
formed as it is a useful tool in assessment of biomarker accu-
racy.12,13 The ROC plots were obtained by plotting all
sensitivity values (true positive fraction) on the y-axis against
their equivalent (1-specificity) values (false positive fraction)
for all available thresholds on the x-axis (MedCalc for Win-
dows 8.1.1.0, Medcalc Software, Mariakerke, Belgium). The
area under the curve (AUC) was calculated to provide a sum-
mary of overall classifier effectiveness. In our study, we con-
sider AUC values ranging from 0.5!0.7 as poor, 0.7!0.8 as
average, 0.8!0.9 as good and >0.9 as outstanding.
For multivariate analysis of biomarker combinations,
logistic regression (LR) analysis of the serum biomarker levels
in these patients groups was performed. As an additional
measure of the potential of these biomarkers to distinguish
between control and cancer samples, a commonly used inter-
nal validation technique known as leave-one-out cross-valida-
tion (LOOCV) was performed.14,15 During the LOOCV pro-
cedure data from a single observation is removed from the
dataset, and the remaining samples are then utilized to con-
struct a LR model. The ‘‘test’’ sample is presented to the
trained model and the performance assessed, LOOCV contin-
ues until each observation is designated as the ‘‘test.’’ Thus,
the LOOCV provides a more conservative estimate of model
performance. LR, LR ROC curves and LOOCV evaluation
were carried out in the open source R statistical computing
environment (http://www.r-project.org/).
Results
Clinical data
Table 1 shows that the mean age of the female control group
(n ¼ 15) was 54 SD 6 8 years (range 35–81 years) and the
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Table 1. Patient data table
Control (m) Control(f) Breast CRC Small cell Adeno Squamous
n 15 15 33 32(17 male/
15 female)
12(7 male/
5 female)
25(14 male/
11 female)
18(10 male/
8 female)
Age 5966 5468 57613 64610 62611 65610 6567
Stage IIIC/IV IIIB/IIIC/IV IIIB/IV IIIB/IV IIIB/IV
Patient data table including number of samples, average age plus/minus standard deviation and disease staging for controls, breast cancer, CRC
and lung cancer (small cell lung carcinoma, lung adenocarcinoma and squamous cell carcinoma of the lung).
Figure 1. (a,b) Box-and-Whisker plots and Bar charts comparing AHSG, C3, CLI, HP and SAA levels in Breast cancer serum samples
compared to a control group. Box-and-Whisker plots represent data with boxes ranging from the 25th to the 75th percentile of the
observed distribution of values. The bold line of the box displays the median value for serum levels of AHSG, C3, CLI, HP and SAA in
breast cancer compared to controls. Whiskers span minimum to maximum observed values. The bar charts display the mean and standard
deviation for AHSG, C3, CLI, HP and SAA levels in breast cancer serum samples compared to controls. (*p  0.05: significant; **p  0.01:
very significant).
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mean age of the male control group (n ¼ 15) was 59 SD
6 6 years (range 38–78 years). In the cancer groups, the
mean age was 57 SD 6 13 years (range 31–79 years) for
patients with breast cancer (n ¼ 33), 64 SD 6 10 years
(range 41–82 years) for patients with CRC (n ¼ 31, 17
males/15 females), 62 SD 6 11 years (range 30–79 years)
for patients with small cell lung cancer (n ¼ 12, 7 males/5
females), 65 SD 6 10 years (range 33–84 years) for
patients with lung adenocarcinoma (n ¼ 25, 14 males/11
females) and 65 SD 6 7 years (range 35–81 years) for
patients with lung squamous cell carcinoma (n ¼ 18, 10
males/8 females). All the patients with breast cancer were
stages IIIC or IV, the patients with CRC were stages IIIB,
IIIC or IV and the patients with lung cancer were all
stages IIIB or IV.
The data presented here on the control groups for CRC
and the three subtypes of lung cancer are comprised of equal
number of both male (n ¼ 15) and female (n ¼ 15) samples,
with the breast cancer control group being comprised only of
female samples (n ¼ 15). Male and female control groups
were also analyzed individually to identify if any of the can-
didate biomarkers are associated with one gender type over
the other; however, no statistically significant changes were
found in serum samples from male or female as individual
groups in any of the comparisons. Therefore, all data pre-
sented here for control groups is a mixture of both male and
female serum samples with the exception of the breast cancer
group.
In addition, within the breast cancer group, human epi-
dermal growth factor receptor 2 (HER2) and estrogen
Figure 1. Continued
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receptor (ER) status was available to us (from patient pa-
thology reports) across the breast cancer cohort to identify
if any specific biomarkers are associated with these molecu-
lar characteristics. Neither HER2 (n ¼ 19: 4 HER2-positive/
15 HER2-negative; AHSG p ¼ 0.12, C3 p ¼ 0.57, CLI p ¼
0.73, HP p ¼ 0.63, SAA p ¼ 0.23) nor ER (n ¼ 33: 21
ER-positive/12 ER-negative; AHSG p ¼ 0.42, C3 p ¼ 0.46,
CLI p ¼ 0.29, HP p ¼ 0.46, SAA p ¼ 0.77) status were
statistically significant in their association with any unique
changes in abundance levels for the biomarkers discussed
here.
Expression of biomarker panel in breast cancer
To assess the levels of AHSG, C3, CLI, HP and SAA in con-
trol and cancer samples, we assayed serum samples using
ELISAs specific to each of these proteins for 33 patients with
advanced stage breast cancer and compared the results to a
control group. Significant increases in abundance levels for
C3, CLI and SAA in breast cancer sera compared to a control
group were observed. AHSG is shown to be significantly
decreased in cancer samples (Fig. 1a & 1b). Box plot analysis
(Fig. 1a) showed that the median level of AHSG was signifi-
cantly increased in control versus cancer samples (436.0 lg/
Figure 2. (a,b) Box-and-Whisker plots and Bar charts comparing AHSG, C3, CLI, HP and SAA levels in CRC serum samples compared to
control groups. Box-and-Whisker plots represent data with boxes ranging from the 25th to the 75th percentile of the observed distribution
of values. The bold line of the box displays the median value for serum levels of AHSG, C3, CLI, HP and SAA in CRC compared to controls.
Whiskers span minimum to maximum observed values. The bar charts display the mean and standard deviation for AHSG, C3, CLI, HP and
SAA levels in CRC serum samples compared to controls. (*p  0.05: significant; **p  0.01: very significant). E
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ml vs. 356.5 lg/ml, respectively; p  0.01). The median serum
levels in normal compared to cancer samples for C3 (431.8 lg/
ml vs. 723.8 lg/ml, respectively; p  0.01) and CLI (69.2 lg/ml
vs. 96.8 lg/ml, respectively; p  0.01) were also found to be
very significantly different, with a clear increase in the cancer
samples. Box-and-Whisker analysis of the ELISA data for SAA
also demonstrated that the level of this protein was signifi-
cantly elevated in serum from patients with cancer compared
to controls (45.4 lg/ml vs. 172.6 lg/ml, respectively; p  0.05).
Expression of biomarker panel in CRC
The CRC ELISA bar charts demonstrate significant increases
in abundance levels for C3, CLI, HP and SAA in CRC sera
compared to a control group. AHSG was found not to be
significantly changed in CRC (Fig. 2a & 2b). Box-and-
Whiskers plots (Fig. 2a) were also generated for AHSG, C3,
CLI, HP and SAA levels in control and cancer samples from
32 patients with CRC. Data from the control versus CRC sera
analysis showed that median levels for C3 (511.0 lg/ml vs.
1092.6 lg/ml, respectively, p  0.01), CLI (64.6 lg/ml vs.
170.3 lg/ml, respectively, p  0.01), HP (447.4 lg/ml
vs. 1200.2 lg/ml respectively, p  0.01) and SAA (45.4 lg/ml
vs. 528.6 lg/ml, respectively, p  0.01) were all very signifi-
cantly elevated in the cancer group.
Expression of biomarker panel in lung cancer
Box plot analysis of the five-candidate biomarkers in serum
from patients with lung cancer was performed by comparing
the median levels of the control group with that from small
cell, adenocarcinoma and squamous cell carcinoma (Fig. 3a).
Figure 2. Continued
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C3 (517.3 lg/ml vs. 1011.1 lg/ml, 873.8 lg/ml, 1043.4 lg/ml,
respectively; p  0.01), HP (539.3 lg/ml vs. 1838.6 lg/ml,
2126.7 lg/ml, 1652.8 lg/ml, respectively; p  0.01) and SAA
(9.8 lg/ml vs. 172.2 lg/ml, 141.6 lg/ml, 53.8 lg/ml, respec-
tively; p  0.01) were all found to be very significantly ele-
vated in all these lung cancer serum samples (Fig. 3). Median
CLI levels very also found to be significantly increased in ad-
enocarcinoma serum samples compared to controls (47.1 lg/
ml vs. 54.8 lg/ml, respectively, p  0.05). In total, serum
samples of 55 patients with lung cancer (12 small cell, 25 ad-
enocarcinoma and 18 squamous cell carcinoma) were ana-
lyzed. Bar charts representing data collected for lung cancer
samples show significant increases in abundance levels for
C3, HP and SAA for small cell, adenocarcinoma and squa-
mous serum samples compared to their respective control
groups (Fig. 3b).
AUC and LOOCV analysis of individual biomarkers
The area under the receiver-operator characteristic curve
(AUC ROC) value for these five candidate biomarkers was
calculated (Table 2). The AUC for AHSG (0.764) was found
to have good discriminatory power between control and
Figure 3. (a,b) Box-and-Whisker plots and Bar charts comparing AHSG, C3, CLI, HP and SAA levels in Lung cancer serum samples
compared to control groups. Box-and-Whisker plots represent data with boxes ranging from the 25th to the 75th percentile of the observed
distribution of values. The bold line of the box displays the median value for serum levels of AHSG, C3, CLI, HP and SAA in lung cancer
(small cell lung carcinoma, lung adenocarcinoma and squamous cell carcinoma of the lung) compared to controls. Whiskers span minimum
to maximum observed values. The bar charts display the mean and standard deviation for AHSG, C3, CLI, HP and SAA levels in Lung cancer
serum samples compared to controls. (*p  0.05: significant; **p  0.01: very significant).
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breast cancer serum samples according to guidelines pub-
lished by Hosmer and Lemeshow.16 In CRC and the three
subtypes of lung cancer, AHSG was found not have signifi-
cant AUC values when compared to the control groups.
C3 was found to have an AUC value of 0.888 in breast
cancer, 0.901 in CRC, 0.933, 0.938 and 0.933 in small cell
lung cancer (SCLC), lung adenocarcinoma and squamous cell
lung cancer, respectively. These values represent excellent dis-
criminatory power. CLI was calculated to have the highest
AUC values in both breast cancer and CRC (0.83 and 0.98,
respectively). AUC values for CLI in lung cancer were found
not to achieve acceptable discrimination.
AUC values for HP were found to achieve outstanding
discrimination in CRC, SCLC, lung adenocarcinoma and
squamous cell lung cancer (0.958, 0.97, 0.92 and 0.944,
respectively). The AUC value for HP in breast cancer was
low (0.614) and not found to be significant. AUC values for
SAA were found to achieve excellent discrimination in CRC,
SCLC, lung adenocarcinoma and squamous cell lung cancer
(0.873, 0.929, 0.892 and 0.817, respectively). The AUC value
for SAA in breast cancer, similar to HP was low (0.644).
Table 2 also shows LOOCV results for AHSG, C3, CLI,
HP and SAA in breast, CRC, SCLC, lung adenocarcinoma
and squamous cell lung cancer. LOOCV—where for each
member of the training set, using a model built using the
other n  1 members, one tries to predict the class of the
remaining member—was also performed. The results indicate
that in terms of LOOCV the most accurate candidate bio-
markers in their respective groups were CLI in breast cancer
(76%), CLI in CRC (90%), HP in SCLC (88%), C3 in lung
Figure 3. Continued
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adenocarcinoma (89%) with both C3 and HP found to have
identical LOOCV percentages in squamous cell carcinoma of
the lung (87%). Positive likelihood ratios (þLR) and negative
likelihood ratios (LR) are also displayed in Table 2. The
positive likelihood ratio is equal to the true positive rate/false
positive rate (or sensitivity/(1  specificity)) while the nega-
tive likelihood ratio is equal to the false negative rate/true
negative rate (or (1  sensitivity)/specificity).
Multivariate analysis of biomarker panel using LR
Table 2 also shows the best combination of two candidate
biomarkers for distinguishing breast, CRC and lung cancer
(small cell, adenocarcinoma and squamous) groups from
their respective controls was calculated using LR analysis. LR
analysis was performed for all possible combinations of two
candidate biomarkers, with the top combination in terms of
an AUC value presented here. A combination of AHSG þ
C3 was found to give an AUC value of 0.91 for breast cancer,
a combination of CLIþHP gave an AUC value of 0.98 for
CRC, while SCLC had a best combination of C3þSAA giving
an AUC value of 0.97. Interestingly, the best combination of
two candidate biomarkers for both adenocarcinoma and
squamous cell carcinoma of the lung was found to be
HPþSAA, resulting in an AUC value of 0.98. Table 2
includes LOOCV results for the best combination of three
proteins in breast cancer (AHSG þ C3, 82%), CRC (CLI þ
HP, 92%), SCLC (C3 þ SAA, 91%), adenocarcinoma (HP þ
SAA, 96%) and squamous cell carcinoma (HP þ SAA, 84%).
Positive likelihood ratios (þLR) and negative likelihood ratios
(LR) are also displayed in Table 2.
To summarize these findings, Table 3 shows the details of
statistically significant abundance level trends for AHSG, C3,
CLI, HP and SAA in serum samples from the patients with
advanced breast, CRC and lung cancer compared to healthy
individuals. Levels are indicated as increased (:), decreased
(;) or unchanged ($). From these data, it is clear that the
levels of these five APPs are not uniformly changed across
the different cancer types and that distinctive patterns present
distinguish these cancers from each other. Trends for these
five proteins from publications relating to their measurement
Table 2. AUC, LOOCV, þLR and LR values for individual and combined candidate biomarkers
AHSG C3 CLI HP SAA Combination
Breast AHSGþC3
AUC 0.76 0.89 0.83 0.61 0.64 0.91
LOOCV(%) 64.44 73.33 75.55 60.00 66.67 82.22
þLR 4.50 4.50 7.25 1.75 2.60 10.00
LR 0.82 0.33 0.43 1.22 0.67 0.25
CRC CLIþHP
AUC 0.65 0.90 0.98 0.96 0.87 0.98
LOOCV(%) 52.00 80.00 90.00 86.00 78.00 92.00
þLR 1.66 4.33 15.00 9.67 3.57 15.00
LR 0.54 0.25 0.05 0.11 0.25 0.05
Small cell (Lung) C3þSAA
AUC 0.53 0.93 0.53 0.97 0.93 0.97
LOOCV(%) 56.25 84.37 62.50 87.50 81.25 90.63
þLR 3.00 3.00 1.40 11.00 3.00 11.00
LR 0.82 0.11 2.33 0.05 0.11 0.05
Adeno (Lung) HPþSAA
AUC 0.56 0.94 0.71 0.92 0.89 0.98
LOOCV(%) 66.66 88.88 57.77 86.66 71.11 95.55
þLR 7.33 11.50 2.57 5.25 2.13 24.00
LR 1.00 0.11 1.00 0.11 0.11 0.05
Squamous (Lung) HPþSAA
AUC 0.52 0.93 0.65 0.94 0.82 0.98
LOOCV(%) 23.68 86.84 57.89 86.84 68.42 84.21
þLR 2.00 5.00 1.57 5.00 1.57 5.00
LR 1.00 0.11 0.53 0.11 0.25 0.11
Area under the curve (AUC), leave-one-out cross-validation (LOOCV), positive likelihood ratio (þLR) and negative likelihood ratio (LR) results for
AHSG, C3, CLI, HP, SAA and the best performing two protein combination in breast, CRC, small cell carcinoma (lung), adenocarcinoma (lung) and
squamous cell carcinoma (lung) are shown.
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in infection/inflammatory conditions are also shown in the
Table 3, with these data serving as a good control to compare
the cancer-specific trends as well.
Discussion
APPs are characterized by a nonspecific rapid response to
stimuli such as inflammation (infections, autoimmune dis-
eases, etc.) or tissue damage (trauma, surgery, myocardial in-
farction or tumors). Some proteins (e.g., haptoglobin, C3 and
SAA) will increase in response to an acute-phase reaction
and are known as positive APPs. Others (e.g., AHSG)
decrease and are known as negative APPs.
When APPs are found to be differentially expressed
between disease and control populations in proteomics
experiments, researchers often dismiss that these results as
uninteresting because, by definition, these proteins have an
increased or decreased abundance level in many conditions
that cause inflammation. Because these changes are not spe-
cific for a condition or disease, they are often thought to
have little potential as conventional biomarkers for diagnosis
or prognosis. However, the potential of APPs as biomarkers
for cancer may have been underestimated. All the APPs do
not have an increased or decreased abundance level across all
cancer types. A recent review by Pang et al. indicates the
presence of putative APP fingerprints in patients with can-
cer.8 Data was compiled from many international biomarker
discovery studies and merged with data generated by Pang
and colleges. From the overall pattern that was derived from
the compiled data, the altered serum APP profiles of patients
appear to be unique for each type of cancer. For example,
pancreatic cancer is associated with increased levels of serum
a1-antitrypsin, a1-antichymotrypsin, complement factor B
and Leucine-rich glycoprotein, whereas breast cancer is asso-
ciated with enhanced levels of a1-antichymotrypsin, comple-
ment factor B and CLI and decreased Kininogen.
In our study, based on earlier work analyzing serum from
patients with squamous cell carcinoma of the lung,11 we
examined the abundance levels for AHSG, C3, CLI, HP and
SAA in serum samples from patients with advanced breast,
CRC and lung cancer compared to healthy individuals.
AHSG, C3, HP and SAA are considered APPs while CLI is
also called an APP but more often referred to as an abundant
secreted serum glycoprotein that may play a significant role
in tumor growth and metastatic progression.22
SAA is a major acute-phase reactant and has been demon-
strated to mediate proinflammatory cellular responses.23 SAA
is expressed mainly by hepatocytes in the liver. Bacterial lipo-
polysaccharides and several cytokines (not only IL1, IL6 and
TNF but also LIF, CNTF, oncostatin M, IL11 and cardiotro-
phin-1) are involved in the induction of SAA synthesis.24 In
our investigation, we found that SAA levels were significantly
changed between control and cancer groups, particularly in
advanced CRC and subtypes of advanced lung cancer. Subse-
quent ROC curve analysis demonstrated that the AUC value
was high, achieving excellent or outstanding discriminatory
power. However, although the level of SAA in advanced breast
cancer was also significant compared to the control group, the
AUC value was low, indicating poorer discriminatory power.
AHSG and C3 are negative and positive APPs, respectively.
AHSG is a 59 kDa glycoprotein predominantly synthesized in
liver and has recently been shown to be involved in mediating
growth signalling in breast tumor cells.25 In our investigation, dif-
ferential expression of AHSG was found to be significant only in
breast cancer, with decreased abundance levels compared to the
control group. Petrik and coworkers identified one peak using
SELDI-TOF as the AHSG that was less prominent with increas-
ing tumor grade in patients with glioblastoma. AHSG was there-
fore subsequently validated as a survival predictor in glioblas-
toma using ELISA in an independent group of 72 patients with
glioblastoma.26 C3 was found to be elevated in all cancer types
investigated in our study with high AUC values. C3 is a major
component of the complement system and elevated levels of this
APP have previously been reported associated with cancer.27 C3
has previously been found to be elevated in sera from patients
diagnosed with pancreatic adenocarcinoma compared to sera
from normal volunteers using gel electrophoresis.28
CLI is a pleiotropic protein with a broad range of func-
tions including tumor growth and metastatic progression.
The literature links expression levels of CLI (both nuclear
and secreted forms) with CRC.28–31 In CRC, an increase of
secreted CLI expression occurs, whereas the nuclear proapop-
totic form is decreased.32 From the data presented here, it is
also clear based on AUC and LOOCV values that CLI is the
most accurate candidate biomarker for distinguishing CRC
from its control group.
Table 3. abundance level trends for AHSG, C3, CLI, HP and SAA
Protein Breast CRC Small cell (lung) Adeno (Lung) Squamous (Lung) Inflammation/Infection
AHSG ; $ $ $ $ ; [46]
C3 : : : : : : [47]
CLI : : $ : $ : [48]
HP $ : : : : : [49]
SAA : : : : : : [50]
Table showing statistically significant abundance level trends for AHSG, C3, CLI, HP and SAA in serum samples from patients with advanced breast,
CRC and lung cancer compared to healthy individuals. Levels are indicated as increased (:), decreased (;) or unchanged ($). As a reference, levels
for these five proteins are also included for general inflammatory conditions as indicated in the referenced literature.17–21.
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Several studies have shown decreased CLI levels in pros-
tate cancer.33,34 On the other hand, there are also reports on
increased expression of CLI in prostate cancer, specifically af-
ter androgen ablation therapy.35 These opposing results have
been explained by the different isoforms of CLI, for example,
proapoptotic nuclear CLI being decreased, while antiapop-
totic, prosurvival secreted CLI could be increased.
An interesting observation from this data is that CLI lev-
els are increased at a very significant level in both CRC and
breast cancer. CLI was also found to be significantly elevated
in adenocarcinoma of the lung but not in squamous cell or
small cell carcinomas. As the majority of both CRC and
breast cancers are adenocarcinomas, this data suggests a pos-
sible link between higher levels of secreted CLI and
adenocarcinomas.
Haptoglobin is a tetrameric plasma glycoprotein produced
primarily by hepatocytes but reports of extrahepatic site pro-
duction have been reported.36 Its synthesis is induced by vari-
ous cytokines, including IL1, IL6 and CNTF.37 Recently, some
groups have examined the individual HP chains (a and b) and
also various modified forms including glycosylated and deami-
dated variants to establish how significant such isoforms are for
distinguishing between control and cancer groups,38 with initial
results indicate that specific HP isoforms may have a role to
play in the detection of cancer.39,40 Our data indicates that HP
was significantly increased in CRC and the three subtypes of
lung cancer when compared to their respective control groups.
In all cases, high AUC values were achieved indicating excellent
discriminatory power for this individual protein. However, no
significant change was found when advanced breast cancer
serum samples were compared to the control group.
Elevated levels of APPs in the serum of patients with
cancer are generally believed to be of liver origin rather than a
tumor cell product.41 However, there is also evidence in the
literature that APPs could also be directly produced by the
disease tissue. Expression studies show local production of
SAA proteins in histologically normal, inflammatory and tu-
mor tissues.42 For example, Gutfeld and coworkers showed,
using nonradioactive in situ hybridization on paraffin tissue
sections from 26 patients with CRC, detectable SAA mRNA
expression in normal looking colonic epithelium. Expression
was increased gradually as epithelial cells progressed through
dysplasia to neoplasia, with deeply invading colon carcinoma
cells showed the highest levels of SAA. Therefore, using APPs
as part of a diagnostic panel may be more tumor specific that
initially realized. Smeets and coworkers demonstrated that in
human kidney tumors, both tumor and stromal cells produced
haptoglobin mRNA.43 Apparently, ectopic production of pro-
teins is a frequent characteristic of tumors, with APPs proving
to have functional roles in tumor development.43,44
Among the biomarkers most often used to monitor
patients with advanced cancer or to determine recurrence are
cancer antigen 15-3 (CA 15-3), cancer antigen 27.29 (CA
27.29), carcino-embryonic antigen (CEA) and neuron-specific
enolase (NSE). CA 15-3 and CA27.29 are highly associated
with breast cancer and are derived from the MUC1 gene. CA
15-3 is elevated in the serum/plasma of  75% of women with
metastasized breast cancer; however, these levels can also be
raised due to the presence of other conditions or cancers. Pec-
tasides and coworkers found that patients with postsurgical
breast cancer prospectively monitored with simultaneous se-
rum level estimations for CA 15-3 and CEA, resulted in sensi-
tivity values of 68.2 and 34.1% respectively.45 The markers
most often elevated in advanced CRC are CEA and CA 19-9,
but neither of these is useful as a screening test for CRC. More
than 70% of patients with advanced CRC have elevated CEA
levels.46 Some of the tumor markers that may be elevated in
advanced lung cancer are the carcinoembryonic antigen
(CEA) in non-small cell lung cancer and the NSE in SCLC.
Molina and coworkers have recently published on serum
levels of ProGRP (Pro-Gastrin-Releasing Peptide), CEA,
squamous cell carcinoma antigen (SCC), CA 125 (cancer
antigen 125), CYFRA 21-1 (cytokeratin 19 fragments) and
NSE in patients with lung cancer and how these measure-
ments correlated with histology.47,48 It was concluded that
these markers may be useful in the histological differentiation
of non-small cell lung carcinoma (NSCLC) and SCLC.
Patients with SCC serum levels >2 ng/ml were always
NSCLC, while those with SCC <2 ng/ml and ProGRP >100
pg/ml and NSE >35 ng/ml were all patients with SCLC. Cor-
rect classification has important implications for clinical
management and panels of biomarkers that can be used in
combination with histology to accurately diagnose the specific
type of lung cancer would have significant clinical utility.
From the literature, it is clear that while all these bio-
markers are currently used in the clinic, these biomarkers still
suffer from low levels of sensitivity and specificity, highlight-
ing a need for additional biomarkers that will help to improve
the overall accuracy for these tests. One difficulty in interpret-
ing serologic data is the potential for spikes in protein abun-
dance levels due to the presence of infection and signatures
associated with its presence. Therefore, combination of bio-
markers such as CA 15-3 and CEA, which are commonly used
in the clinic together with some of the candidate biomarkers
discussed in our study, may help improve the overall accuracy
for monitoring advanced patients with cancer and help over-
come the problems associated with infection-mediated APP
signatures. Furthermore, the optimum pairs of biomarkers
described here are different in each of the cancer types, and
these cancer-related values should be persistent, whereas infec-
tion-related values would be expected to spike and to be less
specific for any pair of APPs. Additionally, in terms of clinical
management, other symptoms of infection would be apparent.
Prostate-specific antigen (PSA), an FDA-approved bio-
marker, has been found to be reasonably successful for pros-
tate cancer diagnosis; however, false positives and negatives
are common.49 However, generally single biomarkers lack the
sensitivity and specificity required for them to be considered
worthwhile diagnostics. To overcome this problem, panels of
biomarkers are now seen as providing that extra sensitivity
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and specificity to increase the overall accuracy of diagnostic
tests.50 We investigated various combinations of two candi-
date biomarkers using LR analysis, to examine if the AUC
values for individual markers for each of the cancer types
could be improved upon. Our data revealed that specific
combinations of two candidate biomarkers outperformed
(breast, lung adenocarcinoma and squamous cell carcinoma
of the lung) or equalled (CRC and small cell lung carcinoma)
their single counterpart. The combinations for breast cancer
(AHSG þ C3), CRC (CLI þ HP) and SCLC (C3 þ SAA)
were all found to be different from each other. Interestingly,
the best combination of two candidate biomarkers for both
lung adenocarcinoma and squamous cell carcinoma of the
lung was found to be HP þ SAA. This data supports the
possibility that patterns of altered serum APP in patients
with different cancers exist as the best combinations were
found to be different with the exception of lung adenocarci-
noma and squamous cell carcinoma of the lung.
Counter-intuitively, combining the two candidate bio-
markers with the best AUC values together using LR analysis
did not always results in the best combination in terms of ac-
curacy. For example, the best individual candidate bio-
markers in the breast cancer comparison were C3 (AUC ¼
0.89, LOOCV ¼ 73%) and CLI (AUC ¼ 0.83, LOOCV ¼
76%). However, after analysis of all possible combination of
two biomarkers, it was found that AHSGþC3 (AUC ¼ 0.91,
LOOCV ¼ 82%) was found to be the best combination. The
reasons for this antagonism are not entirely clear but this
highlights the fact that members of a biomarker panel need
not necessarily have the best individual score for distinguish-
ing between groups with the real value of these biomarkers
being recognized when used in combination.
In our study, we included both AUC and LOOCV values
for all individual and combined biomarkers. ROC curves can
sometimes present an overly optimistic result and the pres-
ence of LOOCV values helps to balance the results and paint
a more realistic picture as regards the accuracy of candidate
biomarkers. For example, in the dataset presented here, the
AUC and LOOCV values for CLI in CRC were 0.98 and 90%
respectively, but it is likely that the 90% value based on the
LOOCV calculation better reflects the true accuracy for this
candidate biomarker.
A variety of cytokines, chemokines and growth factors are
produced by tumor cells and by different cells in the local tu-
mor environment. This signature of active molecules is likely to
differ between tumor types and disease stages resulting in the
stimulation of APPs that reflect the type and stage of the malig-
nancy. Although individual APPs may not satisfactory diagno-
sis biomarkers, in combination or with other serum biomarkers
may enable more sensitive and specific tests. Therefore APPs
may represent a worthwhile component in a panel of bio-
markers that represent the tumor microenvironment. Our data
indicate that specific patterns of altered serum APPs exist in
patients with different cancers and further research is warranted
to assess the value of theses patterns in applications such as
diagnosis of recurrence and monitoring of therapy effectiveness.
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